Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Sarcopenia Clinical Trials Market

ID: MRFR/HS/39179-HCR
128 Pages
Rahul Gotadki
Last Updated: April 06, 2026
Sarcopenia Clinical Trials Market Research Report By Phase (Phase II, Phase III, Phase IV), By Treatment (Muscle-building drugs, Growth hormone therapy, Physical therapy, Nutritional supplements), By Indication (Age-related sarcopenia, Cancer-related sarcopenia, Cachexia, Other) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Phase (USD Billion)
      1. 4.1.1 Phase II
      2. 4.1.2 Phase III
      3. 4.1.3 Phase IV
    2. 4.2 Healthcare, BY Treatment (USD Billion)
      1. 4.2.1 Muscle-building drugs
      2. 4.2.2 Growth hormone therapy
      3. 4.2.3 Physical therapy
      4. 4.2.4 Nutritional supplements
    3. 4.3 Healthcare, BY Indication (USD Billion)
      1. 4.3.1 Age-related sarcopenia
      2. 4.3.2 Cancer-related sarcopenia
      3. 4.3.3 Cachexia
      4. 4.3.4 Others
    4. 4.4 Healthcare, BY Region (USD Billion)
      1. 4.4.1 North America
        1. 4.4.1.1 US
        2. 4.4.1.2 Canada
      2. 4.4.2 Europe
        1. 4.4.2.1 Germany
        2. 4.4.2.2 UK
        3. 4.4.2.3 France
        4. 4.4.2.4 Russia
        5. 4.4.2.5 Italy
        6. 4.4.2.6 Spain
        7. 4.4.2.7 Rest of Europe
      3. 4.4.3 APAC
        1. 4.4.3.1 China
        2. 4.4.3.2 India
        3. 4.4.3.3 Japan
        4. 4.4.3.4 South Korea
        5. 4.4.3.5 Malaysia
        6. 4.4.3.6 Thailand
        7. 4.4.3.7 Indonesia
        8. 4.4.3.8 Rest of APAC
      4. 4.4.4 South America
        1. 4.4.4.1 Brazil
        2. 4.4.4.2 Mexico
        3. 4.4.4.3 Argentina
        4. 4.4.4.4 Rest of South America
      5. 4.4.5 MEA
        1. 4.4.5.1 GCC Countries
        2. 4.4.5.2 South Africa
        3. 4.4.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Pfizer (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Novartis (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Bristol-Myers Squibb (US)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Eli Lilly and Company (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 AstraZeneca (GB)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Roche (CH)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Sanofi (FR)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Amgen (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Merck & Co. (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY PHASE
    4. 6.4 US MARKET ANALYSIS BY TREATMENT
    5. 6.5 US MARKET ANALYSIS BY INDICATION
    6. 6.6 CANADA MARKET ANALYSIS BY PHASE
    7. 6.7 CANADA MARKET ANALYSIS BY TREATMENT
    8. 6.8 CANADA MARKET ANALYSIS BY INDICATION
    9. 6.9 EUROPE MARKET ANALYSIS
    10. 6.10 GERMANY MARKET ANALYSIS BY PHASE
    11. 6.11 GERMANY MARKET ANALYSIS BY TREATMENT
    12. 6.12 GERMANY MARKET ANALYSIS BY INDICATION
    13. 6.13 UK MARKET ANALYSIS BY PHASE
    14. 6.14 UK MARKET ANALYSIS BY TREATMENT
    15. 6.15 UK MARKET ANALYSIS BY INDICATION
    16. 6.16 FRANCE MARKET ANALYSIS BY PHASE
    17. 6.17 FRANCE MARKET ANALYSIS BY TREATMENT
    18. 6.18 FRANCE MARKET ANALYSIS BY INDICATION
    19. 6.19 RUSSIA MARKET ANALYSIS BY PHASE
    20. 6.20 RUSSIA MARKET ANALYSIS BY TREATMENT
    21. 6.21 RUSSIA MARKET ANALYSIS BY INDICATION
    22. 6.22 ITALY MARKET ANALYSIS BY PHASE
    23. 6.23 ITALY MARKET ANALYSIS BY TREATMENT
    24. 6.24 ITALY MARKET ANALYSIS BY INDICATION
    25. 6.25 SPAIN MARKET ANALYSIS BY PHASE
    26. 6.26 SPAIN MARKET ANALYSIS BY TREATMENT
    27. 6.27 SPAIN MARKET ANALYSIS BY INDICATION
    28. 6.28 REST OF EUROPE MARKET ANALYSIS BY PHASE
    29. 6.29 REST OF EUROPE MARKET ANALYSIS BY TREATMENT
    30. 6.30 REST OF EUROPE MARKET ANALYSIS BY INDICATION
    31. 6.31 APAC MARKET ANALYSIS
    32. 6.32 CHINA MARKET ANALYSIS BY PHASE
    33. 6.33 CHINA MARKET ANALYSIS BY TREATMENT
    34. 6.34 CHINA MARKET ANALYSIS BY INDICATION
    35. 6.35 INDIA MARKET ANALYSIS BY PHASE
    36. 6.36 INDIA MARKET ANALYSIS BY TREATMENT
    37. 6.37 INDIA MARKET ANALYSIS BY INDICATION
    38. 6.38 JAPAN MARKET ANALYSIS BY PHASE
    39. 6.39 JAPAN MARKET ANALYSIS BY TREATMENT
    40. 6.40 JAPAN MARKET ANALYSIS BY INDICATION
    41. 6.41 SOUTH KOREA MARKET ANALYSIS BY PHASE
    42. 6.42 SOUTH KOREA MARKET ANALYSIS BY TREATMENT
    43. 6.43 SOUTH KOREA MARKET ANALYSIS BY INDICATION
    44. 6.44 MALAYSIA MARKET ANALYSIS BY PHASE
    45. 6.45 MALAYSIA MARKET ANALYSIS BY TREATMENT
    46. 6.46 MALAYSIA MARKET ANALYSIS BY INDICATION
    47. 6.47 THAILAND MARKET ANALYSIS BY PHASE
    48. 6.48 THAILAND MARKET ANALYSIS BY TREATMENT
    49. 6.49 THAILAND MARKET ANALYSIS BY INDICATION
    50. 6.50 INDONESIA MARKET ANALYSIS BY PHASE
    51. 6.51 INDONESIA MARKET ANALYSIS BY TREATMENT
    52. 6.52 INDONESIA MARKET ANALYSIS BY INDICATION
    53. 6.53 REST OF APAC MARKET ANALYSIS BY PHASE
    54. 6.54 REST OF APAC MARKET ANALYSIS BY TREATMENT
    55. 6.55 REST OF APAC MARKET ANALYSIS BY INDICATION
    56. 6.56 SOUTH AMERICA MARKET ANALYSIS
    57. 6.57 BRAZIL MARKET ANALYSIS BY PHASE
    58. 6.58 BRAZIL MARKET ANALYSIS BY TREATMENT
    59. 6.59 BRAZIL MARKET ANALYSIS BY INDICATION
    60. 6.60 MEXICO MARKET ANALYSIS BY PHASE
    61. 6.61 MEXICO MARKET ANALYSIS BY TREATMENT
    62. 6.62 MEXICO MARKET ANALYSIS BY INDICATION
    63. 6.63 ARGENTINA MARKET ANALYSIS BY PHASE
    64. 6.64 ARGENTINA MARKET ANALYSIS BY TREATMENT
    65. 6.65 ARGENTINA MARKET ANALYSIS BY INDICATION
    66. 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY PHASE
    67. 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT
    68. 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION
    69. 6.69 MEA MARKET ANALYSIS
    70. 6.70 GCC COUNTRIES MARKET ANALYSIS BY PHASE
    71. 6.71 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT
    72. 6.72 GCC COUNTRIES MARKET ANALYSIS BY INDICATION
    73. 6.73 SOUTH AFRICA MARKET ANALYSIS BY PHASE
    74. 6.74 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT
    75. 6.75 SOUTH AFRICA MARKET ANALYSIS BY INDICATION
    76. 6.76 REST OF MEA MARKET ANALYSIS BY PHASE
    77. 6.77 REST OF MEA MARKET ANALYSIS BY TREATMENT
    78. 6.78 REST OF MEA MARKET ANALYSIS BY INDICATION
    79. 6.79 KEY BUYING CRITERIA OF HEALTHCARE
    80. 6.80 RESEARCH PROCESS OF MRFR
    81. 6.81 DRO ANALYSIS OF HEALTHCARE
    82. 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    83. 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    84. 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
    85. 6.85 HEALTHCARE, BY PHASE, 2024 (% SHARE)
    86. 6.86 HEALTHCARE, BY PHASE, 2024 TO 2035 (USD Billion)
    87. 6.87 HEALTHCARE, BY TREATMENT, 2024 (% SHARE)
    88. 6.88 HEALTHCARE, BY TREATMENT, 2024 TO 2035 (USD Billion)
    89. 6.89 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
    90. 6.90 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion)
    91. 6.91 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.2.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.2.3 BY INDICATION, 2025-2035 (USD Billion)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.3.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.3.3 BY INDICATION, 2025-2035 (USD Billion)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.4.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.4.3 BY INDICATION, 2025-2035 (USD Billion)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.5.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.5.3 BY INDICATION, 2025-2035 (USD Billion)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.6.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.6.3 BY INDICATION, 2025-2035 (USD Billion)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.7.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.7.3 BY INDICATION, 2025-2035 (USD Billion)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.8.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.8.3 BY INDICATION, 2025-2035 (USD Billion)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.9.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.9.3 BY INDICATION, 2025-2035 (USD Billion)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.10.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.10.3 BY INDICATION, 2025-2035 (USD Billion)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.11.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.11.3 BY INDICATION, 2025-2035 (USD Billion)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.12.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.12.3 BY INDICATION, 2025-2035 (USD Billion)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.13.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.13.3 BY INDICATION, 2025-2035 (USD Billion)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.14.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.14.3 BY INDICATION, 2025-2035 (USD Billion)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.15.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.15.3 BY INDICATION, 2025-2035 (USD Billion)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.16.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.16.3 BY INDICATION, 2025-2035 (USD Billion)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.17.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.17.3 BY INDICATION, 2025-2035 (USD Billion)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.18.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.18.3 BY INDICATION, 2025-2035 (USD Billion)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.19.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.19.3 BY INDICATION, 2025-2035 (USD Billion)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.20.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.20.3 BY INDICATION, 2025-2035 (USD Billion)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.21.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.21.3 BY INDICATION, 2025-2035 (USD Billion)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.22.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.22.3 BY INDICATION, 2025-2035 (USD Billion)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.23.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.23.3 BY INDICATION, 2025-2035 (USD Billion)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.24.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.24.3 BY INDICATION, 2025-2035 (USD Billion)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.25.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.25.3 BY INDICATION, 2025-2035 (USD Billion)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.26.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.26.3 BY INDICATION, 2025-2035 (USD Billion)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.27.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.27.3 BY INDICATION, 2025-2035 (USD Billion)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.28.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.28.3 BY INDICATION, 2025-2035 (USD Billion)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.29.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.29.3 BY INDICATION, 2025-2035 (USD Billion)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY PHASE, 2025-2035 (USD Billion)
      2. 7.30.2 BY TREATMENT, 2025-2035 (USD Billion)
      3. 7.30.3 BY INDICATION, 2025-2035 (USD Billion)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1

Healthcare Market Segmentation

Healthcare By Phase (USD Billion, 2025-2035)

  • Phase II
  • Phase III
  • Phase IV

Healthcare By Treatment (USD Billion, 2025-2035)

  • Muscle-building drugs
  • Growth hormone therapy
  • Physical therapy
  • Nutritional supplements

Healthcare By Indication (USD Billion, 2025-2035)

  • Age-related sarcopenia
  • Cancer-related sarcopenia
  • Cachexia
  • Others